BACKGROUND: The mechanism of action of single-dose nevirapine on reducing mother-to-child transmission of HIV-1 may involve reduction of maternal HIV-1 or prophylaxis of infants. METHODS: In a study that randomized pregnant mothers to HIVNET 012 nevirapine versus short-course antenatal zidovudine, we compared breast milk HIV-1 RNA viral shedding and administration of single-dose nevirapine between mothers who transmitted HIV-1 to their infants at 6 weeks postpartum and those who did not. RESULTS: In multivariate analyses, maximum breast milk HIV-1 RNA levels (hazard ratio [HR] = 2.50, 95% confidence interval [CI]: 1.25 to 4.99; P = 0.01) and nevirapine use (HR = 0.12, 95% CI: 0.02 to 0.97; P = 0.05) were each independently associated with perinatal transmission at 6 weeks postpartum. Mothers who transmitted HIV-1 to their infants had significantly higher HIV-1 RNA levels in their breast milk between the second day and sixth week postpartum. Among mothers with maximum breast milk virus levels less than a median of 3.5 log(10) copies/mL, the administration of nevirapine further decreased HIV-1 transmission risk from 22.2% to 0.0% (P = 0.04). CONCLUSIONS: Peripartum administration of single-dose nevirapine to mother and infant decreases early perinatal HIV-1 transmission by means of breast milk HIV-1 RNA suppression and, independently, by providing the infant with exposure prophylaxis.
RCT Entities:
BACKGROUND: The mechanism of action of single-dose nevirapine on reducing mother-to-child transmission of HIV-1 may involve reduction of maternal HIV-1 or prophylaxis of infants. METHODS: In a study that randomized pregnant mothers to HIVNET 012 nevirapine versus short-course antenatal zidovudine, we compared breast milk HIV-1 RNA viral shedding and administration of single-dose nevirapine between mothers who transmitted HIV-1 to their infants at 6 weeks postpartum and those who did not. RESULTS: In multivariate analyses, maximum breast milk HIV-1 RNA levels (hazard ratio [HR] = 2.50, 95% confidence interval [CI]: 1.25 to 4.99; P = 0.01) and nevirapine use (HR = 0.12, 95% CI: 0.02 to 0.97; P = 0.05) were each independently associated with perinatal transmission at 6 weeks postpartum. Mothers who transmitted HIV-1 to their infants had significantly higher HIV-1 RNA levels in their breast milk between the second day and sixth week postpartum. Among mothers with maximum breast milk virus levels less than a median of 3.5 log(10) copies/mL, the administration of nevirapine further decreased HIV-1 transmission risk from 22.2% to 0.0% (P = 0.04). CONCLUSIONS: Peripartum administration of single-dose nevirapine to mother and infant decreases early perinatal HIV-1 transmission by means of breast milk HIV-1 RNA suppression and, independently, by providing the infant with exposure prophylaxis.
Authors: Louise Kuhn; Moses Sinkala; M P H Chipepo Kankasa; Prisca Kasonde; Donald M Thea; Grace M Aldrovandi Journal: J Acquir Immune Defic Syndr Date: 2006-06 Impact factor: 3.731
Authors: Roger L Shapiro; Ibou Thior; Peter B Gilbert; Shahin Lockman; Carolyn Wester; Laura M Smeaton; Lisa Stevens; S Jody Heymann; Thumbi Ndung'u; Simani Gaseitsiwe; Vladimir Novitsky; Joseph Makhema; Stephen Lagakos; Max Essex Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: Shahin Lockman; Roger L Shapiro; Laura M Smeaton; Carolyn Wester; Ibou Thior; Lisa Stevens; Fatima Chand; Joseph Makhema; Claire Moffat; Aida Asmelash; Patrick Ndase; Peter Arimi; Erik van Widenfelt; Loeto Mazhani; Vladimir Novitsky; Stephen Lagakos; Max Essex Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Paul Thistle; Rachel F Spitzer; Richard H Glazier; Richard Pilon; Gordon Arbess; Andrew Simor; Eleanor Boyle; Inam Chitsike; Tsungai Chipato; Maureen Gottesman; Michael Silverman Journal: Clin Infect Dis Date: 2006-11-22 Impact factor: 9.079
Authors: Glenda E Gray; Michael Urban; Matthew F Chersich; Carolyn Bolton; Ronelle van Niekerk; Avy Violari; Wendy Stevens; James A McIntyre Journal: AIDS Date: 2005-08-12 Impact factor: 4.177
Authors: Susan H Eshleman; Donald R Hoover; Sarah E Hudelson; Shu Chen; Susan A Fiscus; Estelle Piwowar-Manning; J Brooks Jackson; Newton I Kumwenda; Taha E Taha Journal: J Infect Dis Date: 2006-01-11 Impact factor: 5.226
Authors: G C John; R W Nduati; D A Mbori-Ngacha; B A Richardson; D Panteleeff; A Mwatha; J Overbaugh; J Bwayo; J O Ndinya-Achola; J K Kreiss Journal: J Infect Dis Date: 2000-12-15 Impact factor: 5.226
Authors: Raabya Rossenkhan; Vladimir Novitsky; Teresa K Sebunya; Jean Leidner; Jose E Hagan; Sikhulile Moyo; Laura Smeaton; Shahin Lockman; Rosemary Musonda; Thumbi Ndung'u; Simani Gaseitsiwe; Ibou Thior; Mompati Mmalane; Joseph Makhema; M Essex; Roger Shapiro Journal: AIDS Behav Date: 2012-07
Authors: Mark A Winters; Koen K A Van Rompay; Angela D M Kashuba; Nancy S Shulman; Mark Holodniy Journal: Antimicrob Agents Chemother Date: 2010-08-09 Impact factor: 5.191
Authors: Dara A Lehman; Michael H Chung; Grace C John-Stewart; Barbra A Richardson; James Kiarie; John Kinuthia; Julie Overbaugh Journal: AIDS Date: 2008-07-31 Impact factor: 4.177
Authors: James Ndirangu; Johannes Viljoen; Ruth M Bland; Siva Danaviah; Claire Thorne; Philippe Van de Perre; Marie-Louise Newell Journal: PLoS One Date: 2012-12-28 Impact factor: 3.240